By David Sachs

Merck KGaA said that it has partnered with BenevolentAI and Exscientia on an initiative to discover more drugs with artificial intelligence, which the company says will yield higher success rates.

The German science and technology company said on Wednesday that the partnership with the two U.K. AI firms includes access to an AI platform to generate new drug candidates in oncology, cancer, neurology and immunology. BenevolentAI and Exscientia will each receive upfront payments for their work in the low double-digit millions and will be eligible for additional payments depending on net sales.

The deal includes three potential drug targets with the possibility of more in the future, Merck said. Financial details were not disclosed.

Write to David Sachs at david.sachs@wsj.com

(END) Dow Jones Newswires

September 20, 2023 01:50 ET (05:50 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Merck KGAA (TG:MRK)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Merck KGAA.
Merck KGAA (TG:MRK)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Merck KGAA.